FTC targets Novo's Ozempic, others in crackdown on 300-plus 'junk' patent listings in FDA database
Fierce Pharma
APRIL 30, 2024
The U.S. Federal Trade Commission (FTC) is not done with its crackdown on what it views as improper listing of patents with the FDA. | The U.S. FTC is not done with its crackdown on what it views as improper listing of patents in the FDA Orange Book. After an initial round of challenge launched in November against more than 100 patents, the FTC is back targeting another 300-plus patent listings by eight pharma firms.
Let's personalize your content